@longreach (reply broken) Good points.
Just to add:
- The unique point of radiopharma as against another form of medicine such as oncology or weight control that can’t be missed is its unique supply chain which can’t be put in a developing country or far away from the location of use. So the valuation has to absolutely include that aspect.
- We have the first beta in this space and in the clinic. The higher safety, efficacy and higher specificity and sensitivity including day 0 and day 1 imaging (which Bell potter has mentioned) are all to be included in the valuation.
If you consider the above the valuation is very conservative IMO.
@longreach (reply broken) Good points.Just to add:- The unique...
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$7.06 |
Change
-0.400(5.36%) |
Mkt cap ! $2.260B | |||
| Open | High | Low | Value | Volume |
| $7.46 | $7.68 | $7.00 | $6.919M | 955.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3249 | $7.05 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $7.09 | 816 | 1 |
View Market Depth
| Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
| CU6 (ASX) Chart |